Ingrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of TD. VMAT2 has been identified as a pharmacological target for hyperkinetic movement disorders; Ingrezza causes reversible reduction of dopamine release by selectively inhibiting presynaptic VMAT2. Ingrezza is an oral medication that is taken once daily.
If you have a Hayes login, click here to view the full report on the Knowledge Center.